发明名称 |
Method for assay on the effect of vascularization inhibitor |
摘要 |
The present invention provides a method of predicting the antitumor effect of an angiogenesis inhibitor. It is possible to predict the antitumor effect of an angiogenesis inhibitor by evaluating the EOF dependency of a tumor cell for proliferation and/or survival and using the EGF dependency as an indicator. Since the antitumor effect of an angiogenesis inhibitor correlates with the EGF dependency of a tumor cell for proliferation and/or survival, the angiogenesis inhibitors is capable of producing excellent antitumor effect when combined with a substance having EGF inhibitory activity. |
申请公布号 |
US8969344(B2) |
申请公布日期 |
2015.03.03 |
申请号 |
US201213624278 |
申请日期 |
2012.09.21 |
申请人 |
Eisai R&D Management Co., Ltd. |
发明人 |
Matsui Junji;Yamamoto Yuji;Uenaka Toshimitsu |
分类号 |
A61K31/517;A61K31/535;A61K31/47;G01N33/50;G01N33/574 |
主分类号 |
A61K31/517 |
代理机构 |
Fish & Richardson P.C. |
代理人 |
Fish & Richardson P.C. |
主权项 |
1. A method for treating an EGF-dependent cancer, which method comprises administering, to a patient in need thereof, an effective amount of a VEGF receptor kinase inhibitor in combination with an effective amount of a substance having EGF inhibitory activity, wherein the VEGF receptor kinase inhibitor is a compound selected from the group consisting of:
4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide, 4-(3-chloro-4-(ethylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide, N6-methoxy-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide, 4-(3-chloro-4-(methylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide, N6-methoxy-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide and pharmacologically acceptable salts and solvates thereof; and wherein the substance having EGF inhibitor activity is at least one compound selected from the group consisting of: 4-(3-chloro-4-fluorophenylamino)-7-methoxy-6-(3-(4-morpholino) propoxy-quinazoline), 4-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-quinazoline, N-[3-chloro-4-[(3-fluorobenzyl)oxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]-amino]methyl]furan-2-yl]quinazoline-4-amine, N-[4-[N-(3-chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-quinazoline-6-yl]acrylamide, (2E)-N-[4-[(3-chloro-4-fluorophenyl)amino]-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamide, [6-[4-[(4-ethylpiperazine-1-yl)methyl]phenyl]-7H-pyrrolo[2,3-d]pyrimidine-4-yl]-((R)-1-phenylethyl)amine, (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and pharmacologically acceptable salts and solvates thereof. |
地址 |
Tokyo JP |